USA John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in the long-term.   Strategic failure begins when you turn things over to technologists.   “My 18-year-old daughter, Caroline, responded quickly…

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

USA French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic is not without challenges, LFB USA CEO Jose Antonio Moreno Toscano is optimistic that the launches will be a success…

USA Dan Leonard, Kimberly Westrich, and Brian Sils of the National Pharmaceutical Council examine how a new HHS ruling on how US patients pay for medicines could hurt them financially, exacerbating what is already a challenging time in the midst of the COVID-19 pandemic.   The pandemic has been a challenging…

USA Two leading executives in the US generics market outline why robust company culture is key to attracting top talent that might otherwise gravitate towards the traditional research-driven industry.   Talent attraction in the US generics market could potentially become a serious problem in the next few years. Ed Price, president…

USA In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19 crisis, at what stage of development diagnostics and therapeutics for the virus are, and the pandemic’s long-term effects – both…

Korea After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND) approval from the FDA.   Dr Kyung Suk Kim, Corestem’s CEO, recently spoke to PharmaBoardroom to give an update on…

USA As of 11 June 2020, there have been over two million confirmed cases of COVID-19 in the US and over 115,000 deaths, with the US having occupied the leading spot globally in terms of confirmed cases since late-March. While the pandemic has wreaked havoc across the entire country, advocates of…

USA Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the world’s biggest pharma market.   For Jorge Alderete, president Americas & SVP commercial operations at Danish firm ALK, “Market access…

Coronavirus At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack to that of its rivals in developing a vaccine using the innovative but as yet unproven Messenger RNA (mRNA) technology…

Coronavirus In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He explained the firm’s collaboration with US research group BARDA and underscored that Sanofi is committed to bringing vaccines to all…

USA Jorge Alderete, president of ALK Americas, recently spoke to PharmaBoardroom about his 20+ years with the Danish mid-cap, the challenges in communicating the USA’s challenging market access environment to a European HQ, and why new models of patient-doctor interaction and medical distribution are crucial to ALK’s future success.   A…